| 1. |
- Dierig, A., et al.
(författare)
-
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
- 2023
-
Ingår i: Trials. - : BMC. - 1745-6215. ; 24:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a novel oxazolidinone developed by LegoChem Biosciences Inc. that has been evaluated up to phase 2a clinical trials. Since oxazolidinone toxicity can occur late in treatment, LegoChem Biosciences Inc. and the PanACEA Consortium designed DECODE to be an innovative dose-ranging study with long-term follow-up for determining the exposure-response and exposure-toxicity relationship of delpazolid to support dose selection for later studies. Delpazolid is administered in combination with bedaquiline, delamanid and moxifloxacin.Methods: Seventy-five participants with drug-sensitive, pulmonary tuberculosis will receive bedaquiline, delamanid and moxifloxacin, and will be randomized to delpazolid dosages of 0 mg, 400 mg, 800 mg, 1200 mg once daily, or 800 mg twice daily, for 16 weeks. The primary efficacy endpoint will be the rate of decline of bacterial load on treatment, measured by MGIT liquid culture time to detection from weekly sputum cultures. The primary safety endpoint will be the proportion of oxazolidinone class toxicities; neuropathy, myelosuppression, or tyramine pressor response. Participants who convert to negative liquid media culture by week 8 will stop treatment after the end of their 16-week course and will be observed for relapse until week 52. Participants who do not convert to negative culture will receive continuation phase treatment with rifampicin and isoniazid to complete a six-month treatment course.Discussion: DECODE is an innovative dose-finding trial, designed to support exposure-response modelling for safe and effective dose selection. The trial design allows assessment of occurrence of late toxicities as observed with linezolid, which is necessary in clinical evaluation of novel oxazolidinones. The primary efficacy endpoint is the change in bacterial load, an endpoint conventionally used in shorter dose-finding trials. Long-term follow-up after shortened treatment is possible through a safety rule excluding slow-and non-responders from potentially poorly performing dosages.
|
|
| 2. |
- Fissum, Kevin, et al.
(författare)
-
High-resolution measurement of the 12C(γ,p)11B reaction to excited states for Eγ=50–70MeV
- 1998
-
Ingår i: Physical Review C: covering nuclear physics. - 2469-9985. ; 58:4, s. 2167-2173
-
Tidskriftsartikel (refereegranskat)abstract
- Relative population of states in 11B following the 12C(γ,p) reaction has been measured with high resolution using the deexcitation γ-ray technique. The states near 7 MeV in 11B are clearly resolved and the measured population clarifies earlier conflicting data. Comparison of the results with new calculations indicates the importance of both one-nucleon and multinucleon processes.
|
|
| 3. |
|
|
| 4. |
- Sims, D. A., et al.
(författare)
-
(γ,n) study of the isovector quadrupole resonance in 40Ca
- 1997
-
Ingår i: Physical Review C: covering nuclear physics. - 2469-9985. ; 55:3, s. 1288-1294
-
Tidskriftsartikel (refereegranskat)abstract
- The forward-to-backward asymmetry of neutrons emitted in the 40Ca(γ,n0) reaction was measured at photon energies in the range of 27–50 MeV. An energy-dependent asymmetry was observed that is interpreted as evidence of interference between the isovector quadrupole resonance and the giant dipole resonance. Data analysis in terms of semiclassical and direct-semidirect models estimate the isovector quadrupole resonance to be at an excitation energy of 31.0±1.5 MeV, with a width of 16.0±1.5 MeV, and exhausting most of the energy-weighted sum rule for the isovector quadrupole resonance.
|
|
| 5. |
- Wootton, K. P., et al.
(författare)
-
Storage ring lattice calibration using resonant spin depolarization
- 2013
-
Ingår i: Physical Review Special Topics. Accelerators and Beams. - 1098-4402. ; 16:7
-
Tidskriftsartikel (refereegranskat)abstract
- This paper presents measurements of the GeV-scale electron beam energy for the storage rings at the synchrotron light source facilities Australian Synchrotron (AS) and SPEAR3 at SLAC. Resonant spin depolarization was employed in the beam energy measurement, since it is presently the highest precision technique and an uncertainty of order 10(-6) was achieved at SPEAR3 and AS. Using the resonant depolarization technique, the beam energy was measured at various rf frequencies to measure the linear momentum compaction factor. This measured linear momentum compaction factor was used to evaluate models of the beam trajectory through combined-function bending magnets. The main bending magnets of both lattices are rectangular, horizontally defocusing gradient bending magnets. Four modeling approaches are compared for the beam trajectory through the bending magnet: a circular trajectory, linear and nonlinear hyperbolic cosine trajectories, and numerical evaluation of the trajectory through the measured magnetic field map. Within the uncertainty of the measurement the momentum compaction factor is shown to agree with the numerical model of the trajectory within the bending magnet, and disagree with the hyperbolic cosine approximation.
|
|
| 6. |
- Lee, V., et al.
(författare)
-
Imaging high energy photons with PILATUS II at the tagged photon beam at MAX-lab
- 2009
-
Ingår i: Nuclear Instruments & Methods in Physics Research. Section A: Accelerators, Spectrometers, Detectors, and Associated Equipment. - : Elsevier BV. - 0167-5087 .- 0168-9002. ; 603:3, s. 379-383
-
Tidskriftsartikel (refereegranskat)abstract
- In photonuclear experiments precise location of the photon beam relative to the experimental sample is critical. Previously used techniques such as using photographic film to identify the position, intensity and centroid of the beam is time-consuming and a faster method is required. PILATUS is a single-photon-counting pixel detector developed at the Paul Scherrer Institute (PSI), Switzerland. It is a silicon-based, two-dimensional detector with a large dynamic range and zero readout noise. Designed as an X-ray detector, its optimal quantum efficiency is between 3 and 30 keV. This paper reports measurements carried out at the MAX-lab tagged photon facility in Lund, Sweden. The beam endpoint energy of approximately 200 MeV is far above the designed optimal energy detection range of PILATUS, and provides a critical test of the use of PILATUS under high energy conditions. The detector was placed in the photon beam and images were taken both downstream of other experiments, and in close range of a 19 mm collimator. The successful measurements demonstrate the versatility and robustness of the detector and provide an effective way of quickly and accurately monitoring beam position and profile in real time. (C) 2009 Elsevier B.V. All rights reserved.
|
|
